Genenta Science is a clinical‐stage biotechnology company focused on developing innovative gene and cell therapies for cancer. Founded as a spin‐off from the San Raffaele Hospital in Milan, Italy, the company leverages a proprietary platform to engineer hematopoietic stem and progenitor cells as vehicles for targeted cytokine delivery within the tumor microenvironment. Genenta’s approach seeks to combine the precision of gene therapy with the systemic reach of cell therapy to achieve sustained, localized anti‐tumor activity.
The company’s core technology, known as SNIP (Selectively INduced Protein), enables conditional expression of therapeutic cytokines such as interferon‐alpha directly at sites of disease. By integrating a molecular “switch” that responds to an orally administered activator, SNIP allows clinicians to control the timing and dosage of cytokine release, potentially reducing systemic toxicity. This platform underpins Genenta’s lead candidate, temferon, which is currently being evaluated in clinical trials for glioblastoma and ovarian cancer.
Genenta Science has pursued a global clinical strategy, initiating studies in Europe and North America in collaboration with leading academic cancer centers. The company’s pipeline also includes preclinical programs targeting other solid tumors and hematological malignancies. In addition to advancing its own research, Genenta has established partnerships with biotechnology firms and research institutions to explore new applications of its inducible gene‐therapy technology across multiple tumor types.
Headquartered in Milan with operations extending to the United States, Genenta Science is led by an experienced management team with deep expertise in oncology, gene therapy, and pharmaceutical development. The leadership group includes professionals who have held senior roles at major biopharmaceutical companies and academic research organizations. Through strategic collaborations and a focused R&D pipeline, Genenta aims to address unmet needs in cancer treatment by delivering precise, controllable immunotherapies.
AI Generated. May Contain Errors.
